Bioptik Technology (4161) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bioptik Technology (4161) has a cash flow conversion efficiency ratio of 0.055x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$53.21 Million ≈ $1.68 Million USD) by net assets (NT$974.69 Million ≈ $30.71 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Bioptik Technology for the company's overall valuation and market capitalisation.
Bioptik Technology - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Bioptik Technology's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Bioptik Technology Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bioptik Technology ranked by their cash flow conversion efficiency. Explore how high is Bioptik Technology's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bangkok Dec-Con Public Company Limited
BK:BKD
|
-0.006x |
|
OCR Group Bhd
KLSE:7071
|
-0.107x |
|
YATRA ONLINE DL-0001
F:26Y
|
-0.006x |
|
ANAX Metals Ltd
AU:ANX
|
-0.076x |
|
Epitomee Medical Ltd
TA:EPIT
|
-0.416x |
|
Yuyu Pharma
KO:000220
|
0.006x |
|
Samkee Automotive Co. Ltd
KQ:122350
|
0.044x |
|
Mendus AB (publ)
ST:IMMU
|
-0.037x |
Annual Cash Flow Conversion Efficiency for Bioptik Technology (2017–2025)
The table below shows the annual cash flow conversion efficiency of Bioptik Technology from 2017 to 2025. View Bioptik Technology stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$974.69 Million ≈ $30.71 Million |
NT$59.99 Million ≈ $1.89 Million |
0.062x | -64.92% |
| 2024-12-31 | NT$905.27 Million ≈ $28.52 Million |
NT$158.82 Million ≈ $5.00 Million |
0.175x | -29.79% |
| 2023-12-31 | NT$824.15 Million ≈ $25.97 Million |
NT$205.95 Million ≈ $6.49 Million |
0.250x | +225.81% |
| 2022-12-31 | NT$717.83 Million ≈ $22.62 Million |
NT$55.06 Million ≈ $1.73 Million |
0.077x | +229.45% |
| 2021-12-31 | NT$694.54 Million ≈ $21.88 Million |
NT$-41.15 Million ≈ $-1.30 Million |
-0.059x | -763.13% |
| 2020-12-31 | NT$735.66 Million ≈ $23.18 Million |
NT$6.57 Million ≈ $207.09K |
0.009x | -83.27% |
| 2019-12-31 | NT$768.38 Million ≈ $24.21 Million |
NT$41.03 Million ≈ $1.29 Million |
0.053x | +3.64% |
| 2018-12-31 | NT$811.73 Million ≈ $25.57 Million |
NT$41.83 Million ≈ $1.32 Million |
0.052x | +314.97% |
| 2017-12-31 | NT$887.42 Million ≈ $27.96 Million |
NT$11.02 Million ≈ $347.16K |
0.012x | -- |
About Bioptik Technology
Bioptik Technology Incorporation engages in the manufacturing, wholesale, and retail of biotechnology and medical equipment in Taiwan and internationally. The company offers blood glucose, cholesterol, uric acid, hemoglobin and acid multi-function monitoring systems under the EasyMate, EasySure, and EasyTouch brand name, as well as PeTouch, a glucose monitoring system for dogs and cats. It also p… Read more